Arlin B. Rogers - DVM, PhD

Arlin B. Rogers
Director of Tufts Discovery Pathology
Liver Carcinogenesis




Arlin B. Rogers, DVM, PhD, Associate Professor, Dr. Rogers received his DVM from the University of Illinois and completed a combined PhD/anatomic pathology residency program at Colorado State University. He is an ACVP-certified veterinary pathologist whose primary interest is research on the role of sex in chronic liver diseases and cancer. As author or co-author of more than 100 peer-reviewed publications, his work on sex-dependent pituitary hormones is changing the way human and animal diseases like chronic hepatitis and fatty liver may be managed in the future. In addition to his own independent research, Dr. Rogers collaborates widely with other academic investigators studying chronic digestive diseases. Additionally, he is the Director of Tufts Discovery Pathology, a service center supporting drug discovery and development for biopharmaceutical companies and contract research organizations throughout Massachusetts. As a diagnostic pathologist, Dr. Rogers evaluates surgical biopsies, performs diagnostic and forensic autopsies, and contributes to 4th year veterinary student and resident training. He is the Director of the first year veterinary course in General Pathology, and lectures in several others.



  • BS - University of Illinois at Urbana-Champaign - 1988
  • DVM - University of Illinois at Urbana-Champaign - 1990
  • MS - University of Illinois at Urbana-Champaign - 1992
  • PhD - Colorado State University - 2001

Board Certification

  • American College of Veterinary Pathologists
  1. Livanos, A.E., Greiner, T.U., Vangay, P., Pathmasiri, W., Stewart, D., McRitchie, S., Li, H., Chung, J., Sohn, J., Kim, S., Gao, Z., Barber, C., Kim, J., Ng, S., Rogers, A.B., Sumner, S., Zhang, X.-S., Cadwell, K., Knights, D., Alekseyenko, A., B'ckhed, F., Blaser, M.J. 2016. Antibiotic-mediated gut microbiome perturbation accelerates development of type 1 diabetes in mice. Nature Microbiology.
  2. Zhang, S., Kim, W., Pham, T.T., Rogers, A.B., Houghton, J.M., Moss, S.F. 2016. Native and bone marrow-derived cell mosaicism in gastric carcinoma in H. pylori-infected p27-deficient mice. Oncotarget.
  3. Nolte, T., Brander-Weber, P., Dangler, C., Deschl, U., Elwell, M.R., Greaves, P., Hailey, R., Leach, M.W., Pandiri, A.R., Rogers, A., Shackelford, C.C., Spencer, A., Tanaka, T., Ward, J.M. 2016. Nonproliferative and proliferative lesions of the gastrointestinal tract, pancreas and salivary glands of the rat and mouse. Journal of Toxicologic Pathology.
  4. Wilson, J.E., Petrucelli, A.S., Chen, L., Koblansky, A.A., Truax, A.D., Oyama, Y., Rogers, A.B., Brickey, W.J., Wang, Y., Schneider, M., Mühlbauer, M., Chou, W.-C., Barker, B.R., Jobin, C., Allbritton, N.L., Ramsden, D.A., Davis, B.K., Ting, J.P.Y. 2015. Inflammasome-independent role of AIM2 in suppressing colon tumorigenesis via DNA-PK and Akt. Nature Medicine.
  5. Zhang, S., Lee, D.S., Morrissey, R., Aponte-Pieras, J.R., Rogers, A.B., Moss, S.F. 2015. Early or late antibiotic intervention prevents helicobacter pylori-induced gastric cancer in a mouse model. Cancer Letters.
  6. Zhang, S., Lee, D.S., Morrissey, R., Aponte-Pieras, J.R., Rogers, A.B., Moss, S.F. 2015. Erratum to 'Early or late antibiotic intervention prevents helicobacter pylori-induced gastric cancer in a mouse model' [Cancer lett. 355 (1) (2014) 106-112] DOI: 10.1016/j.canlet.2014.09.010. Cancer Letters.
  7. Song, G., Darr, D.B., Santos, C.M., Ross, M., Valdivia, A., Jordan, J.L., Midkiff, B.R., Cohen, S., Nikolaishvili-Feinberg, N., Miller, C.R., Tarrant, T.K., Rogers, A.B., Dudley, A.C., Perou, C.M., Zamboni, W.C. 2014. Effects of tumor microenvironment heterogeneity on nanoparticle disposition and efficacy in breast cancer tumor models. Clinical Cancer Research.
  8. Cox, L.M., Yamanishi, S., Sohn, J., Alekseyenko, A.V., Leung, J.M., Cho, I., Kim, S.G., Li, H., Gao, Z., Mahana, D., Zárate Rodriguez, J.G., Rogers, A.B., Robine, N., Loke, P., Blaser, M.J. 2014. Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. Cell.
  9. Hartwell, H.J., Petrosky, K.Y., Fox, J.G., Horseman, N.D., Rogers, A.B. 2014. Prolactin prevents hepatocellular carcinoma by restricting innate immune activation of c-Myc in mice. Proceedings of the National Academy of Sciences of the United States of America.
  10. Zhang, S., Lee, D.S., Morrissey, R., Aponte-Pieras, J.R., Rogers, A.B., Moss, S.F. 2014. Early or late antibiotic intervention prevents Helicobacter pylori-induced gastric cancer in a mouse model. Cancer Letters.
  11. Nisimova, L., Wen, S., Cross-Knorr, S., Rogers, A.B., Moss, S.F., Chatterjee, D. 2014. Role of Raf kinase inhibitor protein in Helicobacter pylori-mediated signaling in gastric cancer. Critical Reviews in Oncogenesis.

General Research Interests

  • My lab studies the influence of sex on liver cancer vulnerability. Males develop the primary liver cancer hepatocellular carcinoma (HCC) more than twice as often as females. Using molecular approaches and rodent models we are exploring the mechanistic basis for this in order to develop new therapies for prevention and treatment in men and women.

Selected Research Projects

  • Role of Prolactin in Liver Cancer Prevention: The aim of this project is to show how the estrogen-sensitive pituitary hormone prolactin protects the liver from chronic injury and cancer by modulating the amplitude of innate immune signaling in hepatocytes.
  • Epigenetic Basis of Male Liver Cancer Susceptibility. The aim of this project is to show how liver masculinization initiated by testosterone and effected through growth hormone creates an inherent state of vulnerability to cancer in males through STAT5B-dependent chromatin remodeling.

Research and Clinical Interests

  • Liver Carcinogenesis
  • Chronic GI and Liver Disease
  • Comparative Pathology
  • Diagnostic Anatomic Pathology

Research Interests by Organ System and Disease

Oncology and Cancer Research and Clinical Trials
  • Liver oncology